Q-omics provides the consensus-scored VN1R1 profile across patient tissues and cancer cell-line models. VN1R1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, VN1R1 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, VN1R1 RNA expression shows 19,690 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, LIHC, and THYM as cancer lineages where VN1R1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VN1R1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VN1R1 survival associations across molecular data types. VN1R1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VN1R1 RNA expression–survival associations across cancer types. High VN1R1 expression shows unfavorable associations in MESO, BRCA and THCA, but favorable associations in UCS, ACC and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for VN1R1 RNA expression.
This table summarizes VN1R1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for VN1R1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VN1R1 shows lower tumor expression in UCEC and higher tumor expression in LIHC, CHOL, BRCA, PRAD and KIRC. The LIHC box plot shows higher VN1R1 RNA expression in tumor versus normal tissue (log2 FC = +0.583, t-test p < 0.001).
This table shows molecular features associated with VN1R1 in patient tissues and cancer cell lines. In patient samples, VN1R1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, VN1R1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
